Unknown Jun

Shenzhen Unknown Jun Biotechnology Co., Ltd. was established in 2017 and is currently a domestic AI pharmaceutical company focusing on gut microbiota therapy. It aims to achieve disease remission or treatment through microbiome technology, AI technology, and bioinformatics technology, using live biotherapeutic products and microbial small molecule modulators. Relying on artificial intelligence and gut microbiome technology, Unknown Jun independently developed core algorithms and built a microbiome drug production platform. Based on the specificity of gut microbiota in patients with different indications, it conducts targeted research and development of microbiome drugs, effectively pushing microbiome pharmaceutics from scientific exploration at the laboratory stage to industrialization, and driving the pharmaceutical industry into a new blue ocean.

Unknown Jun's core R&D team is composed of scientists from internationally renowned universities and research institutions such as the Broad Institute, Harvard University, MIT, Stanford University, Icahn School of Medicine at Mount Sinai, and Johns Hopkins University. The drug development team has R&D work experience at internationally renowned pharmaceutical and biotechnology companies such as Pfizer, Novartis, WuXi AppTec, and Bristol-Myers Squibb. The clinical team has more than 20 years of experience in drug clinical trials, regulatory submissions, and FDA drug review. The scientific advisory board is composed of academicians of the Chinese Academy of Sciences and the US National Academy of Sciences, former FDA drug review experts, and renowned experts in the pharmaceutical industry.

To date, the main team members of the company have published more than 200 articles, with nearly 20,000 total citations, including more than 30 articles published in world-renowned academic journals such as Nature, Science, Cell, and their sub-journals. Unknown Jun attaches great importance to independent intellectual property work. The team has applied for 22 patents, including 3 granted invention patents, 2 granted utility model patents, and 8 invention patent applications in progress, including 1 PCT international patent. The company has obtained 25 software copyrights.